Format

Send to

Choose Destination
Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.

KIF5B-RET fusions in lung adenocarcinoma.

Author information

1
Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. tkkohno@ncc.go.jp

Abstract

We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.

Comment in

PMID:
22327624
PMCID:
PMC6430196
DOI:
10.1038/nm.2644
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center